BriaCell Therapeutics Corp [NASDAQ: BCTX] closed the trading session at $2.11 on 2025-07-09. The day’s price range saw the stock hit a low of $2.05, while the highest price level was $2.36.
The stocks have a year to date performance of -86.07 percent and weekly performance of -26.22 percent. The stock has been moved at -78.04 percent over the last six months. The stock has performed -38.66 percent around the most recent 30 days and changed -45.34 percent over the most recent 3-months.
If compared to the average trading volume of 1.62M shares, BCTX reached to a volume of 6594886 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BriaCell Therapeutics Corp [BCTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCTX shares is $32.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCTX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for BriaCell Therapeutics Corp shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 14, 2022.
The Price to Book ratio for the last quarter was 1.11, with the Price to Cash per share for the same quarter was set at 1.84.
BCTX stock trade performance evaluation
BriaCell Therapeutics Corp [BCTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -26.22. With this latest performance, BCTX shares dropped by -38.66% in over the last four-week period, additionally sinking by -78.04% over the last 6 months – not to mention a drop of -75.10% in the past year of trading.
BriaCell Therapeutics Corp [BCTX]: An insightful look at the core fundamentals
Return on Equity for this stock declined to -167.50%, with Return on Assets sitting at -167.50%.
Earnings per share (EPS) analysis for BriaCell Therapeutics Corp [BCTX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BriaCell Therapeutics Corp go to 31.60%.
BriaCell Therapeutics Corp [BCTX]: Institutional Ownership
There are presently around $10.88%, or 11.74% of BCTX stock, in the hands of institutional investors.
